Sunday, March 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

NIH Awards Ebola Funding to Geneva Foundation, BioFactura

by Global Biodefense Staff
September 15, 2014
Ebola Vaccine Research

BioFactura, Inc. today announced it will serve as a collaborator on a grant awarded to the Geneva Foundation for Ebola drug development.

The funding will be provided under a Partnerships for Biodefense grant from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID). The project team is led by the Geneva Foundation of Seattle, Wa., and includes partners at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Fraunhofer USA Center for Molecular Biotechnology.

During the 5-year grant, the team aims to develop an effective monoclonal antibody (mAb)-based drug against Sudan ebolavirus.

Currently, there are no established treatments for Ebola infection. Over the past five years, three Ebola outbreaks involving a Sudan strain of the virus have occurred. The need for strain-specific Ebola countermeasures is imperative for treating infected patients and effectively containing outbreaks. The research team looks forward to developing a promising and urgently needed Ebola treatment that targets the Sudan strain of the virus.

BioFactura develops and commercializes high-value novel and generic biopharmaceuticals (biosimilars) using its patented StableFast Biomanufacturing Platform. The company accomplishes this mission through partnering and licensing agreements with academic institutions, federal laboratories, and mid- to large-pharma companies.

The Geneva Foundation, is a non-profit organization headquartered in Tacoma, WA. Established in April 1993, Geneva’s mission is to support and advance innovative medical research and excellence in education within the U.S. military. The Geneva Foundation connects military researchers to educational and research opportunities in a variety of therapeutic areas to help shape the future of military medicine.

Source: BioFactura press release, adapted.

Tags: EbolaNIH

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC